Boston Scientific still market outperform, JMP says

Boston Scientific Corp. was maintained by JMP Securities analyst Robert C. Faulkner at a market outperform rating after Johnson & Johnson released forecasts for acquisition target Guidant Corp. Boston Scientific also has an offer to acquire Guidant pending. The all-important 2008 forecasts were omitted, Faulkner said. That is the expected time for the U.S. launch of the stent, which is the key driver for all bidding parties. The new Guidant estimates still make it an attractive acquisition for Boston Scientific. Shares of the Natick, Mass., medical device company were up $0.19, or 0.74%, at $26 on volume of 4,321,800 shares versus the three-month running average of 5,410,510 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.